Profile data is unavailable for this security.
About the company
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
- Revenue in JPY (TTM)1.26tn
- Net income in JPY434.01bn
- Incorporated1943
- Employees7.78k
- LocationChugai Pharmaceutical Co Ltd15F, Nihonbashi Mitsui Tower2-1-1, Nihonbashi-Muro-machiCHUO-KU 103-8324JapanJPN
- Phone+81 332816611
- Fax+81 332812828
- Websitehttps://www.chugai-pharm.co.jp
More ▼
Mergers & acquisitions
| Acquired company | 4519:TYO since announced | Transaction value |
|---|---|---|
| Renalys Pharma Inc | 29.72% | 203.17m |
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 684.84bn | 165.07bn | 8.21tn | 20.24k | 49.69 | 6.50 | -- | 11.99 | 1.17 | 1.17 | 4.84 | 8.97 | 0.5312 | 1.71 | 5.75 | 1,530,951.00 | 12.82 | 12.67 | 14.40 | 14.00 | 85.49 | 85.64 | 24.14 | 20.06 | 6.20 | -- | 0.0014 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
| Takeda Pharmaceutical Co Ltd | 4.46tn | 112.93bn | 8.93tn | 47.46k | 77.69 | 1.16 | 10.38 | 2.00 | 72.26 | 72.26 | 2,834.46 | 4,838.54 | 0.2926 | 1.17 | 6.17 | 94,080,250.00 | 0.7418 | 1.71 | 0.8772 | 2.04 | 65.33 | 67.66 | 2.54 | 5.99 | 0.6548 | 3.49 | 0.3884 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| UCB SA | 1.24tn | 241.41bn | 9.85tn | 9.38k | 40.74 | 5.48 | 28.43 | 7.94 | 6.86 | 6.86 | 35.27 | 50.96 | 0.4174 | 1.46 | 4.26 | 730,219.70 | 8.12 | 4.98 | 10.21 | 6.20 | 73.38 | 71.71 | 19.45 | 13.00 | 1.01 | 11.23 | 0.2291 | 34.22 | 17.14 | 4.60 | 210.50 | 6.16 | 1.84 | 2.31 |
| Merck KGaA | 3.86tn | 535.56bn | 10.07tn | 62.35k | 18.81 | 1.92 | 11.41 | 2.61 | 6.79 | 6.79 | 48.92 | 66.55 | 0.4209 | 1.97 | 5.04 | 340,025.90 | 5.85 | 6.04 | 7.23 | 7.70 | 58.69 | 61.15 | 13.91 | 13.80 | 0.9686 | 18.28 | 0.2943 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
| Regeneron Pharmaceuticals Inc | 2.19tn | 694.72bn | 12.97tn | 15.41k | 19.14 | 2.72 | 16.67 | 5.92 | 41.96 | 41.55 | 131.98 | 295.71 | 0.3663 | 0.6934 | 2.40 | 930,752.80 | 11.62 | 16.41 | 13.00 | 18.57 | 86.56 | 87.14 | 31.72 | 36.23 | 3.56 | -- | 0.0797 | 1.50 | 0.9921 | 11.04 | 3.10 | 5.31 | 14.58 | -- |
| Chugai Pharmaceutical Co Ltd | 1.26tn | 434.01bn | 15.58tn | 7.78k | 35.19 | 7.54 | -- | 12.39 | 263.73 | 263.73 | 764.40 | 1,230.91 | 0.5379 | 1.41 | 3.59 | -- | 18.56 | 19.40 | 21.83 | 23.54 | 71.09 | 66.75 | 34.50 | 31.46 | 3.56 | 583.66 | -- | 40.95 | 7.46 | 9.84 | 12.06 | 15.11 | 12.69 | 17.27 |
| Sanofi SA | 8.47tn | 895.13bn | 17.16tn | 84.59k | 19.24 | 1.31 | 13.70 | 2.03 | 4.03 | 6.37 | 38.15 | 59.04 | 0.3599 | -- | 10.62 | -- | 3.95 | 4.87 | 5.10 | 6.07 | 72.07 | 70.15 | 10.99 | 14.05 | -- | 57.94 | 0.2209 | 77.13 | 5.49 | 4.57 | -10.13 | -16.67 | -- | 5.18 |
| GSK plc | 6.81tn | 1.19tn | 18.39tn | 68.63k | 15.58 | 5.39 | 8.77 | 2.70 | 1.39 | 1.39 | 7.95 | 4.02 | 0.5418 | 1.54 | 4.57 | -- | 10.43 | 7.00 | 16.02 | 10.95 | 72.67 | 71.30 | 19.25 | 15.49 | 0.5416 | 16.90 | 0.5262 | 69.37 | 4.11 | 6.05 | 121.98 | 5.07 | 5.92 | -7.97 |
| Bristol-Myers Squibb Co | 7.36tn | 1.08tn | 18.89tn | 32.50k | 17.56 | 6.62 | 11.18 | 2.57 | 3.46 | 3.46 | 23.64 | 9.18 | 0.5278 | 5.03 | 5.02 | 1,482,892.00 | 7.73 | 3.92 | 10.43 | 5.05 | 72.63 | 76.32 | 14.64 | 8.34 | 1.14 | 16.84 | 0.7091 | 122.54 | -0.2195 | 2.54 | 178.83 | -- | 11.73 | 0.658 |
| Vertex Pharmaceuticals Inc | 1.83tn | 603.67bn | 19.06tn | 6.10k | 32.05 | 6.69 | 42.81 | 10.40 | 15.33 | 15.33 | 46.51 | 73.49 | 0.4982 | 1.14 | 6.55 | -- | 16.41 | 13.29 | 19.40 | 15.74 | 86.24 | 86.99 | 32.94 | 25.71 | 2.46 | -- | -- | -- | 8.90 | 14.10 | 838.09 | 7.83 | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Chugai Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
10.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 05 Feb 2026 | 49.06m | 2.92% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 24.38m | 1.45% |
| Amova Asset Management Co., Ltd.as of 06 Feb 2026 | 24.17m | 1.44% |
| Daiwa Asset Management Co. Ltd.as of 30 Jan 2026 | 22.79m | 1.36% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 14.80m | 0.88% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Feb 2026 | 13.50m | 0.80% |
| Wellington Management Co. LLPas of 30 Jan 2026 | 10.22m | 0.61% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 8.77m | 0.52% |
| Geode Capital Management LLCas of 12 Feb 2026 | 8.62m | 0.51% |
| T. Rowe Price International Ltd.as of 05 Feb 2026 | 6.99m | 0.42% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
